Avastin for small bowel cancers – pro
There is limited published literature to support Avastin. Aydin published a small study that concluded that although there was no significant difference in any of the outcomes, the use of bevacizumab together with chemotherapy is a more effective treatment approach compared with chemotherapy alone, and it does not cause an excess of significant toxicity. A 2019 systematic review concluded that there was a significant improvement in mean overall survival with the addition of bevacizumab with chemotherapy versus chemotherapy alone. The use of bevacizumab with chemotherapy, likewise improved progression-free survival and objective response rate compared to chemotherapy alone. Continued use of bevacizumab beyond the first progression also appeared to show benefit.
Aydin DE et al, valuation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.Clin Colorectal Cancer. 2017 Mar;16(1):78-83.
John Paulo Vergara, Danielle Benedict Leoncio Sacdalan, Madelaine Amurao-Amante, Dennis Lee Sacdalan, Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. https://journals.sagepub.com/doi/full/10.1177/2036361318825413 2019